Source: Annual Congress 2005 - Advancements in diffuse parenchymal lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. T. Uh, Y. K. Kim, K. U. Kim, G. I. Lim, D. J. Na, Y. T. Chung (Seoul, Daejeon, Republic Of Korea). Inhalation therapy of interferon-gamma in patients with idiopathic pulmonary fibrosis. Eur Respir J 2005; 26: Suppl. 49, 1799

Member's Comments

No comment yet.

Related content which might interest you: Role of interleukin-10 in idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 23: 179-180 Year: 2004 Anti-fibrotic role of inhaled interferon-γ in idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: clinical aspects Year: 2015 The effect of pentoxifylline on IL-12 and IL-18 release by alveolar macrophages in sarcoidosis and hypersensitivity pneumonitis versus idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017 Year: 2017 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 In-vivo and in-vitro production of interferon gamma in pediatric patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 140s Year: 2002 Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Aerosolized interferon-gamma (IFN-γ) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007 Effects of short-term pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 628s Year: 2006 Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis Source: Eur Respir Rev, 28 (153) 190022; 10.1183/16000617.0022-2019 Year: 2019 CTGF and TNFa expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis before and after treatment with azathioprine and interferon-g Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Pulse therapy of corticosteroids in idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical aspects in pulmonary fibrosis Year: 2010 Negative outcome of prednisone in possible idiopathic pulmonary fibrosis Source: International Congress 2016 – IPF clinical Year: 2016 Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 57 (5) 2002559; 10.1183/13993003.02559-2020 Year: 2021 Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis Source: Eur Respir J 2006; 28: 496-504 Year: 2006 Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 High-dose acetylcysteine in idiopathic pulmonary fibrosis Source: ISSN=ISSN 1810-6838, ISBN=, page=358 Year: 2006